1.660EUR+34.30%Mkt Cap: 163.26M EURP/E: —Last update: 2026-05-14
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)0.81
PEG—
P/B-7.50
P/S18.13
EV/EBITDA-2.84
EV/Revenue16.82
EPS (TTM)-0.55
EPS (Forward)2.15
Cash Flow & Leverage
FCF Yield-20.87%
FCF Margin-378.39%
Operating CF-32.56M EUR
CapEx (TTM)2.35M EUR
Net Debt/EBITDA0.22
Net Debt-11.74M EUR
Technical
SMA 501.226 (+35.4%)
SMA 2001.549 (+7.2%)
Beta0.81
S&P 52W Chg24.23%
Avg Vol (30d)460.74K
Avg Vol (10d)474.18K
Technical Indicators
RSI (14)74.8
MACD0.0384
MACD Signal0.0072
MACD Hist.+0.0312
BB Upper1.486 EUR
BB Middle1.258 EUR
BB Lower1.029 EUR
BB Width36.41%
ATR (14)0.1277 EUR
Vol Ratio (20d)10.02x
52W Range
1.03054% of range2.200
52W High2.200 EUR
52W Low1.030 EUR
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin-1764.51%
Oper. Margin-689.55%
ROE226.58%
ROA-78.41%
Revenue Growth-46.70%
Earnings Growth—
Balance Sheet
Debt/Equity-1.04
Current Ratio1.27
Quick Ratio1.14
Book Value/Sh-0.2320 EUR
Cash/Share0.3660 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.93.83M
Float65.91M
Insiders25.70%
Institutions8.17%
Analyst Consensus
Rating—
Target (Mean)5.350 EUR
Target Range4.500 EUR – 6.200 EUR
# Analysts2
Company
Market Cap163.26M EUR
Enterprise Value151.46M EUR
Revenue (TTM)9.01M EUR
Gross Profit-34.62M EUR
Net Income (TTM)-49.18M EUR
Revenue/Share0.1010 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees163
Last Price1.660 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0010331421